Related references
Note: Only part of the references are listed.A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index
Tateaki Naito et al.
CANCER (2022)
Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial
Ghazal Sadat Askarpour Moezian et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2022)
The interplay of immunology and cachexia in infection and cancer
Hatoon Baazim et al.
NATURE REVIEWS IMMUNOLOGY (2022)
The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
Hidetaka Wakabayashi et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2021)
Amelioration of anxiety, depression, and chemotherapy related toxicity after crocin administration during chemotherapy of breast cancer: A double blind, randomized clinical trial
Roham Salek et al.
PHYTOTHERAPY RESEARCH (2021)
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines
J. Arends et al.
ESMO OPEN (2021)
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study
KenjiY Morimoto et al.
ONCOIMMUNOLOGY (2021)
A Randomized, Controlled, Parallel-Group, Trial on the Effects of Melatonin on Fatigue Associated with Breast Cancer and Its Adjuvant Treatments
Abdolazim Sedighi Pashaki et al.
INTEGRATIVE CANCER THERAPIES (2021)
Nausea and Vomiting in Advanced Cancer
Rudolph M. Navari
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hironobu Hashimoto et al.
LANCET ONCOLOGY (2020)
Management of Cancer Cachexia: ASCO Guideline
Eric J. Roeland et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer
Hironori Fujii et al.
ANTICANCER RESEARCH (2020)
Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study
Ilanna Marques Gomes da Rocha et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2019)
A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia
Satoshi Hamauchi et al.
CANCER (2019)
Anamorelin (ONO-7643) for the Treatment of Patients With Non-Small Cell Lung Cancer and Cachexia: Results From a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Japanese Patients (ONO-7643-04)
Nobuyuki Katakami et al.
CANCER (2018)
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials
Jennifer S. Temel et al.
LANCET ONCOLOGY (2016)
Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
Koichi Takayama et al.
SUPPORTIVE CARE IN CANCER (2016)
Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC
Hongjie Zhang et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Correlation Between the International Consensus Definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and Patient-Centered Outcomes in Advanced Non-Small Cell Lung Cancer
Thomas W. LeBlanc et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2015)
Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS)
Thomas W. LeBlanc et al.
SUPPORTIVE CARE IN CANCER (2015)
Cancer cachexia, mechanism and treatment
Tomoyoshi Aoyagi et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2015)
Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome
David C. Currow et al.
FUTURE ONCOLOGY (2014)
Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile
Claudio Pietra et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2014)
Understanding the mechanisms and treatment options in cancer cachexia
Kenneth Fearon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study
Jose M. Garcia et al.
SUPPORTIVE CARE IN CANCER (2013)
Weight loss in cancer patients: a plea for a better awareness of the issue
Luigi Mariani et al.
SUPPORTIVE CARE IN CANCER (2012)
Definition and classification of cancer cachexia: an international consensus
Kenneth Fearon et al.
LANCET ONCOLOGY (2011)
Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers
Jose M. Garcia et al.
GROWTH HORMONE & IGF RESEARCH (2009)
Cachexia: A new definition
William J. Evans et al.
CLINICAL NUTRITION (2008)
Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: Results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers
Jose M. Garcia et al.
ONCOLOGIST (2007)
Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects
T Akamizu et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial
NM Neary et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)